The estimated Net Worth of Health Llc Pure Tech is at least $1.27 Billion dollars as of 9 February 2021. Health Tech owns over 1,000,000 units of Karuna Therapeutics Inc stock worth over $793,757,004 and over the last 7 years Health sold KRTX stock worth over $474,823,214.
Health has made over 9 trades of the Karuna Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Health sold 1,000,000 units of KRTX stock worth $118,000,000 on 9 February 2021.
The largest trade Health's ever made was selling 6,161,531 units of Karuna Therapeutics Inc stock on 18 December 2019 worth over $7,393,837. On average, Health trades about 1,290,287 units every 111 days since 2018. As of 9 February 2021 Health still owns at least 2,406,564 units of Karuna Therapeutics Inc stock.
You can see the complete history of Health Tech stock trades at the bottom of the page.
Health's mailing address filed with the SEC is 6 TIDE STREET, , BOSTON, MA, 02210.
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy, and Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: